An Open-label, Single-Dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A

Abstract Purpose Hemophilia A represents up to 80% of all hemophilia cases in China. In patients with this condition, bleeding can be prevented and controlled by administering clotting factor VIII (FVIII). Since their initial availability, recombinant FVIII products have undergone several iterations...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical therapeutics 2017-07, Vol.39 (7), p.1313-1319
Hauptverfasser: Liu, Hongzhong, MD, Wu, Runhui, MD, PhD, Hu, Pei, MD, Sun, Feifei, MD, PhD, Xu, Lihong, MD, Liang, Yali, MS, Nepal, Sunil, PhD, Qu, Peng Roger, PhD, Huard, Francois, MS, MBA, Korth-Bradley, Joan M., PharmD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!